- Trial Phase
- Preclinical
- Time to Market
- Unknown — still preclinical; IND-enabling studies not yet started; likely 5+ years away from any potential approval assuming financing and successful clinical development
- Why 2/10
- ALN1003 is preclinical only — no IND filed, no human trials, and no FDA catalyst date scheduled in the next ~12 months. The company had only ~$0.354M cash as of March 31, 2026, with runway into Q2 2026, making survival the immediate binary, not a drug catalyst.
ALN1003 is too early-stage to drive a catalyst-based trade. The only near-term binary is financing: watch for a dilutive equity offering or reverse split. Without a capital infusion, the company cannot fund IND-enabling studies. This is a speculative story stock, not a drug catalyst play.
Price Chart
Executive Summary
ALN1003 is Alaunos Therapeutics' only pipeline candidate — an oral, non-hormonal small molecule in preclinical development for obesity and metabolic disorders. Early mouse studies show promising weight loss and metabolic improvements, but the program is at its earliest stage (no IND, no human data). The company faces an existential cash crisis: only ~$0.354M as of March 31, 2026, with runway extending only into Q2 2026. With zero analyst buy ratings, a going-concern warning, and intense competition from well-capitalized GLP-1 players (Novo Nordisk, Eli Lilly, Amgen), ALN1003 is a high-risk, long-shot preclinical asset at a company fighting for survival.
How It Works
ALN1003 is an oral small-molecule drug for obesity and metabolic disorders that works through a non-hormonal, non-incretin mechanism — meaning it does not mimic hormones like GLP-1 (the mechanism behind Ozempic, Wegovy, Mounjaro). Its exact molecular target is not publicly detailed, but it targets multiple drivers of metabolic dysfunction including insulin resistance, fat-tissue signaling, and liver fat metabolism.
Trial Status
ALN1003 has completed several non-GLP diet-induced obesity (DIO) mouse studies showing dose-dependent body weight loss (up to -30.5% in high-dose), reduced liver weight, improved metabolic biomarkers (HOMA-IR, NAFLD Activity Scores), and favorable adipose endocrine signaling. However, these studies are non-GLP, early-stage, and had confounders including dose aversion and dehydration. No IND has been filed. No human clinical trials have been conducted. The company continues preclinical activities to inform IND-enabling study planning, contingent on financing.
The Two-Sided Case
Upcoming Catalysts
- Financing announcement — any equity offering, reverse split, or partnership deal to extend cash runway (imminent given ~$0.354M cash)
- IND filing or IND-enabling study initiation — contingent on financing, no timeline given
- Further preclinical data updates — the company continues releasing mouse study analyses periodically
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Alaunos Therapeutics, Inc. 8-K TCRT ·Originating report